Xia Wu

6.0k citations

135 papers · 3.4k indexed · 2 hit papers · h-index 31

Impact in

Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Oncology top 5%
- Cancer Immunotherapy and Biomarkers

Papers in ⓘ

Molecular Biology 57
- RNA modifications and cancer 9
- Advanced biosensing and bioanalysis techniques 9
- Inflammasome and immune disorders 7
- RNA Interference and Gene Delivery 6
Oncology 27
- Cancer Immunotherapy and Biomarkers 10

Co-authors: Qiaohong Wang (4 shared papers)Yanbing Ding (1 shared paper)Yiming Li (1 shared paper)Yanjun Zhong (1 shared paper)Junke Long (1 shared paper)Wen Di (4 shared papers)Lifang Yang (8 shared papers)Zhuan Zhou (7 shared papers)
Journals: Scientific Reports (5 papers)International Immunopharmacology (3 papers)PLoS ONE (3 papers)OncoTargets and Therapy (2 papers)Cancer Letters (2 papers)
Partner nations: China United States Saudi Arabia

In The Last Decade

Xia Wu

126 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer 2021 · 207 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Nature Communications
2020 International Journal of Antimicrobial Agents

Peers

Countries citing papers authored by Xia Wu

Since Specialization

Citations

This map shows the geographic impact of Xia Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xia Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xia Wu more than expected).

Fields of papers citing papers by Xia Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xia Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xia Wu. The network helps show where Xia Wu may publish in the future.

Co-authors

The 25 scholars most cited alongside Xia Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xia Wu Line = papers co-authored together Xia Wu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 135 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The epidemiology, diagnosis and treatment of COVID-19 International Journal of Antimicrobial Agents ·Pan Zhai, Yanbing Ding, Xia Wu, Junke Long, Yanjun Zhong, Yiming Li Hit paper breakdown →	2020	645
2	Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer Nature Communications ·Fei Tian, Shaohua Zhang, Chao Liu, Ziwei Han, Yuan Liu, Jinqi Deng, Yike Li, Xia Wu, Lili Cai, Lili Qin, Qinghua Chen, Yang Yuan, Yi Liu, Yulong Cong, Baoquan Ding, Zefei Jiang, Jiashu Sun Hit paper breakdown →	2021	207
3	Pseudoprogression and hyperprogression after checkpoint blockade International Immunopharmacology ·Qiaohong Wang, Jingze Gao, Xia Wu	2018	117
4	Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling Cancer Letters ·Xia Wu, Zhuan Zhou, San Xu, Chaoliang Liao, Xi Chen, Bo Li, Jinwu Peng, Dan Li, Lifang Yang	2020	113
5	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment International Immunopharmacology ·Qiaohong Wang, Xia Wu	2017	108
6	VCAM-1 secreted from cancer-associated fibroblasts enhances the growth and invasion of lung cancer cells through AKT and MAPK signaling Cancer Letters ·Zhuan Zhou, Qin Zhou, Xia Wu, San Xu, Xiaohong Hu, Xuxiu Tao, Bo Li, Jinwu Peng, Dan Li, Liangfang Shen, Ya Cao, Lifang Yang	2020	80
7	Tumor‐derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression Hepatology ·Chu‐Bin Luo, Haoyang Xin, Zheng‐Jun Zhou, Zhiqiang Hu, Rongqi Sun, Na Yao, Qi‐Man Sun, Uyunbilig Borjigin, Xia Wu, Jia Fan, Xiaowu Huang, Shao‐Lai Zhou, Jian Zhou	2022	78
8	Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells Journal of Cancer ·Tuan Wang, Xia Wu, Mus’ab Al Rudaisat, Yinjing Song, Hao Cheng	2020	73
9	HPV E7 inhibits cell pyroptosis by promoting TRIM21-mediated degradation and ubiquitination of the IFI16 inflammasome International Journal of Biological Sciences ·Yinjing Song, Xia Wu, Yaohan Xu, Jiang Zhu, Jiaying Li, Ziqi Zou, Luxia Chen, Boya Zhang, Chunting Hua, Rui Han, Qiaoli Zheng, Qiang Zhou, Qingqing Wang, Hao Cheng	2020	71
10	Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer International Immunopharmacology ·Qiaohong Wang, Weihua Lou, Wen Di, Xia Wu	2017	71
11	Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models Cancer Immunology Immunotherapy ·Qiaohong Wang, Jingze Gao, Wen Di, Xia Wu	2020	68
12	The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy Cancer Immunology Immunotherapy ·Xia Wu, Qinmei Feng, Ying Wang, Jun Shi, Hailiang Ge, Wen Di	2009	65
13	Intratumoral CD8+ Cytotoxic Lymphocyte Is a Favorable Prognostic Marker in Node-Negative Breast Cancer PLoS ONE ·Zonglin Chen, Xianyu Chen, Enxiang Zhou, Ganlong Chen, Ke Qian, Xia Wu, Xiongying Miao, Zhonghua Tang	2014	53
14	LMP1‐positive extracellular vesicles promote radioresistance in nasopharyngeal carcinoma cells through P38 MAPK signaling Cancer Medicine ·Zhibao Zhang, Xuehui Yu, Zhuan Zhou, Bo Li, Jinwu Peng, Xia Wu, Xiangjian Luo, Lifang Yang	2019	52
15	Rifampicin inhibits rotenone-induced microglial inflammation via enhancement of autophagy NeuroToxicology ·Yanran Liang, Tianen Zhou, Ying Chen, Danyu Lin, Xiuna Jing, Sudan Peng, Dezhi Zheng, Zhifen Zeng, Ming Lei, Xia Wu, Kaixun Huang, Lianhong Yang, Songhua Xiao, Jun Liu, Enxiang Tao	2017	47
16	Biomacromolecule‐Functionalized AIEgens for Advanced Biomedical Studies Small ·Feng Wu, Xia Wu, Zhijuan Duan, Yu Huang, Xiaoding Lou, Fan Xia	2019	47
17	Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction Journal of Medicinal Chemistry ·Mingze Qin, Yangyang Meng, Haoshen Yang, Lei Liu, Haotian Zhang, Simeng Wang, Chunyang Liu, Xia Wu, Di Wu, Ye Tian, Yunlei Hou, Yanfang Zhao, Yajing Liu, Congjun Xu, Lihui Wang	2021	46
18	Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold European Journal of Medicinal Chemistry ·Mingze Qin, Qi Cao, Xia Wu, Chunyang Liu, Shuaishuai Zheng, Hongbo Xie, Ye Tian, Jun Xie, Yanfang Zhao, Yunlei Hou, Xian Zhang, Boxuan Xu, Haotian Zhang, Xiaobo Wang	2019	45
19	Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules Clinical Epigenetics ·Chen Chen, Xiaojie Huang, Wei Yin, Muyun Peng, Fang Wu, Xia Wu, Jingqun Tang, Mingjiu Chen, Xiang Wang, Alicia Hulbert, Malcolm V. Brock, Wenliang Liu, James G. Herman, Fenglei Yu	2020	44
20	TOSA Institutional Knowledge (InK) - Institutional Knowledge at Singapore Management University (Singapore Management University) ·Baihua Zheng, Xia Wu, Xing Jin, Dik Lun Lee	2005	43

About Xia Wu

Xia Wu is a scholar working on Molecular Biology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Epidemiology, having authored 135 papers that have together received 3.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), RNA modifications and cancer (9 papers), Advanced biosensing and bioanalysis techniques (9 papers), Inflammasome and immune disorders (7 papers), Cancer-related molecular mechanisms research (7 papers), Ovarian cancer diagnosis and treatment (6 papers), RNA Interference and Gene Delivery (6 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Cancer Research (583 citations), Oncology (900 citations), Infectious Diseases (441 citations), Immunology (483 citations) and Molecular Biology (1.4k citations). Xia Wu has collaborated with scholars based in China, United States and Saudi Arabia. Frequent co-authors include Qiaohong Wang, Yanbing Ding, Yiming Li, Yanjun Zhong, Junke Long, Wen Di, Lifang Yang, Zhuan Zhou, Yuping Gong and Jinwu Peng. Their work appears in journals such as Scientific Reports, International Immunopharmacology, PLoS ONE, OncoTargets and Therapy and Cancer Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact